The Triumph of Hope Over Science
By Mark Derr,
New York Times
| 02. 24. 2004
After I was diagnosed with Parkinson's disease two years ago,
at the relatively young age of 52, I read everything I could
about the condition's usual "progression" — an
odd word for degeneration. The worst-case prognosis is grim:
a long slide into physical and mental incapacity.
That is not going to happen to me, I said, as I began measuring
my physical decline. I am young enough that I may be able to
benefit from advances in medicine, especially in brain research.
Maybe with new medications I would be able to put off taking
L-dopa, the best drug for Parkinson's but one that loses its
effectiveness over time. Surely better treatments will become
available, I told myself.
So why didn't I welcome the news that researchers in South
Korea were able to clone a human embryo and extract viable stem
cells from it? After all, one of the researchers said their
goal was "not to clone humans, but to understand the causes
of diseases" — and one of the diseases named most
often was Parkinson's. Scientists say they may one...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...